Attached files
file | filename |
---|---|
EX-32.2 - EXHIBIT 32.2 - Astria Therapeutics, Inc. | tm211035d2_ex32-2.htm |
EX-32.1 - EXHIBIT 32.1 - Astria Therapeutics, Inc. | tm211035d2_ex32-1.htm |
EX-31.2 - EXHIBIT 31.2 - Astria Therapeutics, Inc. | tm211035d2_ex31-2.htm |
EX-31.1 - EXHIBIT 31.1 - Astria Therapeutics, Inc. | tm211035d2_ex31-1.htm |
EX-21.1 - EXHIBIT 21.1 - Astria Therapeutics, Inc. | tm211035d2_ex21-1.htm |
EX-10.10 - EXHIBIT 10.10 - Astria Therapeutics, Inc. | tm211035d2_ex10-10.htm |
EX-10.9 - EXHIBIT 10.9 - Astria Therapeutics, Inc. | tm211035d2_ex10-9.htm |
EX-10.3 - EXHIBIT 10.3 - Astria Therapeutics, Inc. | tm211035d2_ex10-3.htm |
10-K - 10-K - Astria Therapeutics, Inc. | tm211035-1_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1) | Registration Statement (Form S-1 Nos. 333-225410 and 333-225734) of Catabasis Pharmaceuticals, Inc., |
2) | Registration Statement (Form S-3 No. 333-231441) of Catabasis Pharmaceuticals, Inc., and |
3) | Registration Statement (Form S-8 Nos. 333-206394, 333-210229, 333-216793, 333-223721, 333-229643, 333-239114) pertaining to the equity incentive plans of Catabasis Pharmaceuticals, Inc.; |
of our report dated March 11, 2021, with respect to the consolidated financial statements of Catabasis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Catabasis Pharmaceuticals, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 11, 2021